Global Human Recombinant Insulin Market Research Report 2022

Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
Due to the COVID-19 pandemic, the global Human Recombinant Insulin market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Human Recombinant Insulin market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Human Recombinant Insulin landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Rapid-Acting Human Insulin accounting for % of the Human Recombinant Insulin global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Human Recombinant Insulin include Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. In terms of revenue, the global 3 largest players have a % market share of Human Recombinant Insulin in 2021.
This report focuses on Human Recombinant Insulin volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Human Recombinant Insulin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Human Recombinant Insulin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Rapid-Acting Human Insulin
Regular (Short Acting) Insulin
NPH (Intermediate Acting) Insulin
Long-Acting Human Insulin
Premixed Human Insulins Insulin
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech

Frequently Asked Questions